UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 23 March 2026,
London UK
Admission to trading
In conformity with PRM 1.6.4R, GSK plc notifies the market
that ordinary shares of 31¼ pence each ('Ordinary Shares')
have been admitted to trading as set out in the table below. The
Ordinary Shares have been admitted to trading under existing block
listing admissions of Ordinary Shares in connection with the
"GlaxoSmithKline plc Share Save Plan 2012 and 2022".
|
1a
|
Issuer name
|
GSK plc
|
|
1b
|
Issuer LEI
|
5493000HZTVUYLO1D793
|
|
2
|
Regulated market on which the securities have been admitted to
trading
|
London Stock Exchange - Main Market
|
|
3
|
Name, type and ISIN of the securities
|
Ordinary Shares of 31¼ pence each
ISIN: GB00BN7SWP63
|
|
4
|
Number of further securities admitted to trading covered
by this notification
|
96,525
|
|
5
|
Total number of securities admitted to trading following
admission
|
4,316,176,278
|
|
6
|
Fungibility
|
Fully fungible with existing Ordinary Shares
|
|
7
|
Date range covered by the notification
|
23 January 2026 - 20 March 2026
|
|
8
|
Prospectus information
|
N/A
|
V A Whyte
Company Secretary
23 March 2026
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
23, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|